Nordic Life Science 1
TOP STORIES BUSINESS Applikon Biotechnology is a
company in the area of advanced bioreactor systems for biopharmaceutical production and research. ETINGE WILL acquire all outstanding shares in Applikon Color amet this and will pay approximately EUR 80 million in cash on closing for 100% of the shares. In addition, a maximum earn out of approximately EUR 60 million can be paid out in 2021–2022 if agreed earnings performance is achieved in 2020–2021. ”Applikon Biotechnology has a strong portfolio of world class bioreactor solutions which Dan Pitulia, CEO, Coala Life NEW MA RK E T will be a positive addition to Getinge’s existing offer towards the biopharma segment, the fastest growing area within Life Science,” says Mattias Perjos, President & CEO Getinge. “This deal further broadens our position within solutions for efficient, safe and contamination-free research and production processes.” Applikon is a privately-held company, founded in 1973 and has its head office in Delft, The Netherlands. The company employs approximately 180 employees worldwide and works mainly through a global distribution network. The collaboration with Asahi Kasei includes a development program and research targeting Heart Failure (HF) patients in Japan. HE PARTNERSHIP CONCERNS exclusively the Japanese market and aims to further develop and evaluate the use of the Coala Heart Monitor for remote monitoring and management of patients affected by HF. The device is not approved in Japan, and is only used for research. The intent is to develop and evaluate novel 16 NORDICLIFESCIENCE.ORG digital biomarkers of HF and evaluate the clinical solutions in terms of service feasibility in Japan. “We’re delighted to initiate a collaboration with Asahi Kasei to further explore the unique opportunities of our digital platform and its use in helping to remotely monitor and manage Heart Failure patients,” says Dan Pitulia, CEO, Coala Life. Mattias Perjos, CEO, Getinge